Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | PI103 | 3 | 72 | 0.032 | 3596.5 | 3977.0 | 1175.8 | -1.49 | 0.889 | 0.904 | 1.758 | BT549 PI103 0 3 72 |
| BT-549 | PI103 | 3 | 72 | 0.1 | 2802.8 | 3977.0 | 1175.8 | -1.0 | 0.639 | 0.705 | 1.758 | BT549 PI103 0 3 72 |
| BT-549 | PI103 | 3 | 72 | 0.32 | 1819.5 | 3977.0 | 1175.8 | -0.495 | 0.282 | 0.458 | 1.758 | BT549 PI103 0 3 72 |
| BT-549 | PI103 | 3 | 72 | 1.0 | 1444.0 | 3977.0 | 1175.8 | 0.0 | 0.124 | 0.363 | 1.758 | BT549 PI103 0 3 72 |
| BT-549 | PI103 | 3 | 72 | 3.2 | 1181.0 | 3977.0 | 1175.8 | 0.505 | 0.002 | 0.297 | 1.758 | BT549 PI103 0 3 72 |
| BT-549 | PIK-93 | 3 | 72 | 0.001 | 3882.0 | 4115.3 | 1175.8 | -3.0 | 0.936 | 0.943 | 1.807 | BT549 PIK93 0 3 72 |
| BT-549 | PIK-93 | 3 | 72 | 0.0032 | 3862.3 | 4115.3 | 1175.8 | -2.49 | 0.931 | 0.939 | 1.807 | BT549 PIK93 0 3 72 |
| BT-549 | PIK-93 | 3 | 72 | 0.01 | 3894.3 | 4115.3 | 1175.8 | -2.0 | 0.940 | 0.946 | 1.807 | BT549 PIK93 0 3 72 |
| BT-549 | PIK-93 | 3 | 72 | 0.032 | 3945.8 | 4115.3 | 1175.8 | -1.49 | 0.954 | 0.959 | 1.807 | BT549 PIK93 0 3 72 |
| BT-549 | PIK-93 | 3 | 72 | 0.1 | 3856.8 | 4115.3 | 1175.8 | -1.0 | 0.929 | 0.937 | 1.807 | BT549 PIK93 0 3 72 |
| BT-549 | PIK-93 | 3 | 72 | 0.32 | 3987.3 | 4115.3 | 1175.8 | -0.495 | 0.965 | 0.969 | 1.807 | BT549 PIK93 0 3 72 |
| BT-549 | PIK-93 | 3 | 72 | 1.0 | 3609.0 | 4115.3 | 1175.8 | 0.0 | 0.860 | 0.877 | 1.807 | BT549 PIK93 0 3 72 |
| BT-549 | PIK-93 | 3 | 72 | 3.2 | 3131.3 | 4115.3 | 1175.8 | 0.505 | 0.719 | 0.761 | 1.807 | BT549 PIK93 0 3 72 |
| BT-549 | Sirolimus | 3 | 72 | 0.001 | 2541.0 | 3829.5 | 1175.8 | -3.0 | 0.572 | 0.664 | 1.703 | BT549 Rapamycin 0 3 72 |
| BT-549 | Sirolimus | 3 | 72 | 0.0032 | 2437.3 | 3829.5 | 1175.8 | -2.49 | 0.534 | 0.636 | 1.703 | BT549 Rapamycin 0 3 72 |
| BT-549 | Sirolimus | 3 | 72 | 0.01 | 2443.8 | 3829.5 | 1175.8 | -2.0 | 0.536 | 0.638 | 1.703 | BT549 Rapamycin 0 3 72 |
| BT-549 | Sirolimus | 3 | 72 | 0.032 | 2360.8 | 3829.5 | 1175.8 | -1.49 | 0.506 | 0.616 | 1.703 | BT549 Rapamycin 0 3 72 |
| BT-549 | Sirolimus | 3 | 72 | 0.1 | 2544.3 | 3829.5 | 1175.8 | -1.0 | 0.573 | 0.664 | 1.703 | BT549 Rapamycin 0 3 72 |
| BT-549 | Sirolimus | 3 | 72 | 0.32 | 2333.8 | 3829.5 | 1175.8 | -0.495 | 0.495 | 0.609 | 1.703 | BT549 Rapamycin 0 3 72 |
| BT-549 | Sirolimus | 3 | 72 | 1.0 | 2266.3 | 3829.5 | 1175.8 | 0.0 | 0.470 | 0.592 | 1.703 | BT549 Rapamycin 0 3 72 |
| BT-549 | Sirolimus | 3 | 72 | 3.2 | 2228.5 | 3829.5 | 1175.8 | 0.505 | 0.455 | 0.582 | 1.703 | BT549 Rapamycin 0 3 72 |
| BT-549 | TGX221 | 3 | 72 | 0.001 | 3759.0 | 4003.5 | 1175.8 | -3.0 | 0.930 | 0.939 | 1.768 | BT549 TGX221 0 3 72 |
| BT-549 | TGX221 | 3 | 72 | 0.0032 | 3774.3 | 4003.5 | 1175.8 | -2.49 | 0.934 | 0.943 | 1.768 | BT549 TGX221 0 3 72 |
| BT-549 | TGX221 | 3 | 72 | 0.01 | 3907.8 | 4003.5 | 1175.8 | -2.0 | 0.973 | 0.976 | 1.768 | BT549 TGX221 0 3 72 |
| BT-549 | TGX221 | 3 | 72 | 0.032 | 3676.3 | 4003.5 | 1175.8 | -1.49 | 0.906 | 0.918 | 1.768 | BT549 TGX221 0 3 72 |